Clinical Summary

JCO Precision Oncology

JUNE 2023

Study data from Castle Biosciences’ collaboration with
the National Cancer Institute’s SEER program registries

REFERENCE

Bailey CN, Martin BJ, Petkov VI, et al. 31-gene expression profile testing in cutaneous melanoma and survival
outcomes in a population-based analysis: A SEER collaboration. JCO Precision Oncology. 2023. DOI: 10.1200/
PO.23.00044

  • background

    The DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (Class 1A), intermediate (Class 1B/2A), or high (Class 2B).

  • objective

    In collaboration with the National Cancer Institute (NCI) and SEER program this study aimed to examine the effect of 31-GEP testing on survival outcomes and confirm the prognostic ability of the 31-GEP at the population level.

  • methods

    SEER cancer registries linked CM cases diagnosed from 2016-2018 to data for patients with Stage I-III CM tested with 31-GEP (n=4,687). To assess if patients tested with the 31-GEP had higher survival rates than untested patients a cohort of 31-GEP tested patients (n= 3,258) with complete matching data available was matched to a cohort of non-31-GEP tested patients (n= 9,774) by 11 covariates in a 1:3 ratio.

  • results

    DecisionDx-Melanoma independently riskstratified patients according to their risk of dying from melanoma, consistent with previously published retrospective and prospective studies.

       

Integrating 31-GEP testing with current guidelines can help clinicians make risk-aligned management decisions which may improve patient outcomes and could reduce the melanoma-associated burden on patients and the healthcare system.

In a population-based, clinically tested melanoma cohort, the 31-GEP test successfully stratified patients by their risk of dying from melanoma

Want to learn more about DecisionDx-Melanoma?

Contact us